CCR8 and neoplasm: Intraperitoneal administration of 200 μg of Nb-Fc1A was done at days 4 and 11 of LLC-OVA tumor growth, resulting in an efficient occupation of CCR8 inside the TME (figure 6B), but also in the spleen (online supplemental figure S8A), as illustrated by the prevention of subsequent anti-CCR8 mAb binding.